BiotechTube
Priovant Therapeutics

Priovant Therapeutics

Durham, United States· Est.
priovant.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $285M

Overview

Priovant Therapeutics is an emerging biotech player advancing a pipeline of oral small molecule therapies for severe autoimmune disorders. The company's core asset is brepocitinib, a dual TYK2/JAK1 inhibitor licensed from Pfizer, which is in Phase 3 development for systemic lupus erythematosus (SLE) and non-infectious uveitis. Backed by a strategic partnership with Roivant Sciences, Priovant is positioned to rapidly advance its targeted immunology portfolio in markets with significant commercial potential. The company operates as a private, pre-revenue entity with a focused team driving late-stage clinical development.

Autoimmune DiseasesImmunology

Technology Platform

Small molecule inhibitors targeting intracellular signaling pathways, specifically TYK2 and JAK kinases, for immunology.

Funding History

2
Total raised:$285M
Series B$235M
Series A$50M

Opportunities

The significant unmet medical need in severe autoimmune diseases like SLE and uveitis creates a large addressable market for effective oral therapies.
Positive Phase 3 data could position brepocitinib as a best-in-class TYK2 inhibitor, leading to potential blockbuster sales and strategic partnership or acquisition interest from larger pharmaceutical companies.

Risk Factors

The company faces high clinical risk as its entire value is concentrated on the success of a single asset in two Phase 3 trials.
It also operates in a highly competitive landscape with other TYK2/JAK inhibitors and faces regulatory scrutiny over the safety profile of this drug class.

Competitive Landscape

Priovant competes in the crowded and innovative autoimmune disease space. Key competitors include Bristol Myers Squibb (deucravacitinib, a TYK2 inhibitor approved for psoriasis), AbbVie, Pfizer, and AstraZeneca, all with advanced immunology pipelines. Differentiation will depend on brepocitinib's efficacy, safety, and convenience profile in head-to-head studies and real-world use.

More companies in United States →